Results 21 to 30 of about 22,616 (177)

MicroRNAs as potential biomarkers in adrenocortical cancer: progress and challenges

open access: yesFrontiers in Endocrinology, 2016
Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited therapeutic options. Over the last decade, pan-genomic analyses of genetic and epigenetic alterations and genome-wide expression profile studies allowed major advances in the ...
Nadia eCHERRADI   +2 more
doaj   +1 more source

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma

open access: yesPharmaceuticals, 2023
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts.
Kerstin Michalski   +6 more
openaire   +3 more sources

18F-FDG PET/CT image findings of a dog with adrenocortical carcinoma

open access: yesBMC Veterinary Research, 2022
Background In human medicine, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used to differentiate between benign and malignant adrenal tumors and to identify metastases.
Dohee Lee   +7 more
doaj   +1 more source

Case Report: Adrenocortical carcinoma in children—symptoms, diagnosis, and treatment

open access: yesFrontiers in Endocrinology, 2023
Adrenocortical carcinomas are extremely rare in the paediatric population. Most of them are hormone-secretive lesions; therefore, they should be taken into consideration in a child with signs of precocious puberty and/or Cushing’s syndrome symptoms ...
Estera Zagojska   +3 more
doaj   +1 more source

Radiotherapy in adrenocortical carcinoma [PDF]

open access: yesCancer, 2009
AbstractAdrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of radiotherapy is not defined well and because ACC often is considered radioresistant, the ...
Buelent, Polat   +9 more
openaire   +2 more sources

Virilizing adrenocortical carcinoma in a child: A rare enigma

open access: yesIndian Journal of Endocrinology and Metabolism, 2012
Adrenocortical carcinomas are rare tumors with an incidence of one to two cases per million population and are still more rarer in the pediatric age group.
Varuna Sipayya   +4 more
doaj   +1 more source

Surgical approach to an adrenocortical carcinoma with right atrial extension in a nine-year old male: Our experience

open access: yesJournal of Pediatric Surgery Case Reports, 2020
Adrenocortical carcinoma with intracaval and intra atrial extension is an extremely rare occurrence in the pediatric population. We report the case of a nine‐year‐old male who presented to our outpatient department with facial swelling, weight gain, and ...
Ayesha Saleem   +3 more
doaj   +1 more source

Adrenocortical carcinoma with extension to the inferior vena cava and right atrium: 20-month-old girl with TP53 mutation

open access: yesRadiology Case Reports, 2015
A 20-month-old female presented with respiratory distress and a right adrenal mass extending into the inferior vena cava and right atrium. The mass was initially thought to be neuroblastoma. Pathology later revealed adrenocortical carcinoma.
Terry L. Levin, MD   +3 more
doaj   +1 more source

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy

open access: yesIJU Case Reports, 2020
Introduction Adrenocortical carcinoma is a rare malignant tumor with an unfavorable prognosis in the advanced stage for which second‐/third‐line chemotherapy is not well established.
Akinaru Yamamoto   +8 more
doaj   +1 more source

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma

open access: yesIJU Case Reports, 2023
Introduction Advanced adrenocortical carcinoma has a poor prognosis and is treated with chemotherapy that includes mitotane with etoposide, doxorubicin, and cisplatin as first‐line therapy.
Masaya Senda   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy